Concepedia

George P. Keogh

GP

Statistics

Publications

8

Citations

1.2K

H-Index

8

Active since

2009

Affiliations

Charleston Hematology Oncology Associates(Current)

Moffitt Cancer Center

Rocky Mountain Cancer Centers

Princess Margaret Cancer Centre

Bristol-Myers Squibb (United States)

George P. Keogh is an author at Charleston Hematology Oncology Associates specializing in oncology, medicine, and pharmacotherapy.

Publications per year

2009–2022

8

Publications

8

Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180

Steven P. Treon, Leukothea Ioakimidis, Jacob D. Soumerai et al. · Journal of Clinical Oncology · 2009 · 290 citations · Full text

, , +13

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 278 citations · Full text

, , +16

Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153

David Waterhouse, Edward B. Garon, Jason C. Chandler et al. · Journal of Clinical Oncology · 2020 · 240 citations · Full text

, , +16

Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)

David R. Spigel, Michael McCleod, Robert M. Jotte et al. · Journal of Thoracic Oncology · 2019 · 187 citations

, , +17

Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC)

David R. Spigel, M. Herbert McLeod, Maen Hussein et al. · Annals of Oncology · 2017 · 98 citations · Full text

, , +7

1–5 of 8